NCT05732779 Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients
| NCT ID | NCT05732779 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Florida |
| Condition | Heart Transplant Rejection |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-10-01 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.
Eligibility Criteria
Inclusion Criteria: * Eligible participants are 10-21 years of age * Have received a heart transplant and are followed participating pediatric heart transplant centers * English-speaking or Spanish-speaking * Own a smart-phone or have access to the mobile app through other devices * Are willing to receive information through it * Have a MLVI score of greater than 2.0 over the last year Exclusion Criteria: • Those with cognitive impairments will not be eligible for enrollment due to inability to provide informed assent
Contact & Investigator
Dipankar Gupta, MD
PRINCIPAL INVESTIGATOR
University of Florida
Frequently Asked Questions
Who can join the NCT05732779 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, up to 21 Years, studying Heart Transplant Rejection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05732779 currently recruiting?
Yes, NCT05732779 is actively recruiting participants. Contact the research team at dgupta@ufl.edu for enrollment information.
Where is the NCT05732779 trial being conducted?
This trial is being conducted at Coral Gables, United States, Gainesville, United States, Hollywood, United States, Tallahassee, United States.
Who is sponsoring the NCT05732779 clinical trial?
NCT05732779 is sponsored by University of Florida. The principal investigator is Dipankar Gupta, MD at University of Florida. The trial plans to enroll 100 participants.